Lyft Inc (NASDAQ:LYFT) is expected to provide revised long-term financial targets when it hands down its fourth quarter results, with analysts at Jefferies seeing upside to the rideshare provider’s bookings led by higher pricing.
They forecast fiscal 2024 bookings 3%, or about $470 million, higher than the consensus analyst estimate based on new disclosures on bookings and rides.
Diversified Energy has had its target price and buy recommendation reiterated by house broker Peel Hunt following the open letter yesterday published by members of the US House of Representatives Committee on Energy and Commerce.
“Having reviewed the open letter, we see this as largely a rehash of a Bloomberg Green article published in October 2021,” said Peel Hunt.
US investment bank Citi has expressed scepticism about the recent proposals announced by UK Housing Secretary Michael Gove to address delays in housing developments.
The bank believes these measures will have minimal impact on the current planning system stalemate, foreseeing continued entanglement in the appeals process.
Citi has revised down its forecast for Reckitt Benckiser Group PLC (LSE:RKT, ETR:3RB), reflecting a more cautious assessment of prospects for the consumer goods giant, particularly in the short term.
Citi has reduced its earnings per share (EPS) estimates for Reckitt for the years 2023 and 2024. The 2023 EPS forecast has been lowered by 0.5%, and the 2024 estimate by 2.7%.
Bids for UK companies averaged a 51% premium on firms’ share prices in 2023 as buyers sought out undervalued stocks, according to AJ Bell analysts.
This represents a jump from average premium prices paid during takeovers of 37% in 2022 and 43% in 2021.
Shares in Seeing Machines Ltd (AIM:SEE, OTC:SEEMF) were marked higher in the wake of its 17th major automotive contract for its driver monitoring technology.
The eye-tracking specialist didn’t name the latest customer but said the lifetime value of the new business was US$30 million.
Shares in Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) were marked higher after it unveiled significant progress with its AI-driven programme for the respiratory syncytial virus (RSV).
Using technology, it was able to reduce the timeline for identifying drug candidates to just 10 months. Ordinarily, this discovery phase would take two to four years.